SOURCE-LINKED STUDY SUMMARY
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Abstract summarizedQuality not appraised
- What was studied
- Randomized safety trial comparing oral semaglutide with placebo for cardiovascular death, nonfatal heart attack or stroke.
- Who / model studied
- 3183 people with type 2 diabetes at high cardiovascular risk; median time in the trial was 15.9 months.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Primary cardiovascular events occurred in 3.8% versus 4.8%, meeting the trial's safety criterion. Cardiovascular deaths were 0.9% versus 1.9%; nonfatal heart attacks were 2.3% versus 1.9%, and nonfatal strokes 0.8% versus 1.0%. Digestive adverse events led to more treatment discontinuations with oral semaglutide.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa1901118